Booster vaccination after neonatal priming with acellular pertussis vaccine

J Pediatr. 2010 Apr;156(4):675-8. doi: 10.1016/j.jpeds.2009.12.019.


After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

Trial registration: NCT00289796.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Follow-Up Studies
  • Humans
  • Immunization, Secondary / methods*
  • Infant
  • Infant, Newborn
  • Pertussis Vaccine / administration & dosage*
  • Prognosis
  • Vaccination / methods*
  • Vaccines, Acellular
  • Whooping Cough / prevention & control*


  • Pertussis Vaccine
  • Vaccines, Acellular

Associated data